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Leishmaniasis is a neglected disease that is increasing globally at an alarming rate. Glucantime has been the therapy of choice
for more than 50 years. A recent study reported the antileishmanial activity of copaiba oil against Leishmania amazonensis.
These results led us to investigate morphological and ultrastructural changes in L. amazonensis treated with copaiba oil, using
electron microscopy and ﬂow cytometry to assess speciﬁc organelles as targets for copaiba oil. In the promastigote and axenic
amastigote forms, this copaiba oil caused notable morphological and ultrastructural changes, including extensive mitochondrial
damage and denaturation of the plasma membrane. Copaiba oil treatment also induced a decrease in Rh123 ﬂuorescence,
suggesting interference with the mitochondrial membrane potential and loss of cell viability with an increase in plasma membrane
permeability, as observed by ﬂow cytometry after staining with propidium iodide. In conclusion, copaiba oil could be exploited
for the development of new antileishmanial drugs.
1.Introduction
Parasites of the genus Leishmania cause a wide spectrum
of human infections, ranging from the disﬁguring mucosal
and cutaneous forms of the disease to the life-threatening
visceral form [1–4]. The species and/or strains of the
Leishmania parasites strongly inﬂuence the clinical features
of leishmaniasis, including host immunity [5]. There are
approximately 21 species of Leishmania,t r a n s m i t t e db y
about 30 phlebotomine sandﬂy species [6]. The number of
cases of leishmaniasis is increasing globally at an alarming
rate. According to the World Health Organization, this
group of diseases is endemic in 88 countries in Africa, Asia,
Europe, and North and South America, with a total of 350
million people at risk [7]. Despite its increasing worldwide
incidence, leishmaniasis has become one of the so-called
neglected diseases, with little interest by ﬁnancial donors,
public-health authorities, and professionals to implement
activities to research, prevent, or control the disease [8–10].
During a complex digenetic life cycle, ﬂagellated Leishmania
parasites alternate between promastigote (living in the gut
of their sandﬂy vector) and amastigote forms (living in
their mammalian host), which diﬀer signiﬁcantly in cellular
morphology and ﬂagellum length [11]. The parasites have
developed a variety of adaptive mechanisms to evade the
vertebrate host immune responses, including survival within
the host macrophage [12, 13]. Because leishmaniasis mainly
aﬀects poor countries, research and development of new
drugs have been seriously neglected [6, 8, 10, 14]. The
pentavalent antimonials (Glucantime) have been the therapy
ofchoiceformorethan50years.Althoughthelipidformula-
tionsofamphotericinBareanimportantadvanceintherapy,
their high cost precludes their use [15]. Consequently, there
is an urgent need to discover new drugs that are eﬀective
against leishmaniasis. Plants are very promising subjects,
since they have been important sources of substances with2 Evidence-Based Complementary and Alternative Medicine
many therapeutic uses [16–18]. In addition, the American
ﬂora is one of the world’s wealthiest sources of material
with pharmacological activity, due to its biodiversity [19].
Copaiba oil has been used in folk medicine since the 19th
century[19,20].Theuseofcopaibaoilstotreatleishmaniasis
is cited in several ethnopharmacological studies [21–24]. A
recent study by Santos et al. [25] found that copaiba oils
obtained from diﬀerent species of Copaifera show activity
against promastigote forms of L. amazonensis. Signiﬁcant
antileishmanial activity of copaiba oil from C. reticulata was
demonstrated against axenic amastigote and intracellular
amastigote forms of the parasite. These ﬁndings led us to
investigate the morphological and ultrastructural changes
in L. amazonensis treated with copaiba oil, using elec-
tron microscopy and ﬂow cytometry to investigate speciﬁc
organelles as targets for copaiba oil.
2.MaterialsandMethods
2.1. Plant Material. Copaifera reticulata Ducke was collected
in Bel´ em, state of Par´ a, and deposited in the Herbarium
of the Instituto Nacional de Pesquisas da Amazˆ onia (INPA,
Manaus) under number INPA 61,212.
2.2. Parasites. Leishmania amazonensis MHOM/BR/
75/Josefa strain was isolated from a patient with diﬀuse
cutaneous leishmaniasis by Cesar Augusto Cuba-Cuba
(Universidade de Bras´ ılia, Brazil). Promastigote forms were
cultured at 25◦C in Warren’s medium (brain-heart infusion
plus haemin and folic acid), pH 7.0, supplemented with
10% heat-inactivated foetal bovine serum (FBS) (Gibco
Invitrogen Corporation, New York, USA), in a tissue ﬂask
with weekly transfers. Axenic amastigote cultures obtained
by in vitro transformations of infective promastigotes [26]
were incubated at 32◦C in Schneider’s insect medium (Sigma
Chemical Co., St. Louis, MO, USA), pH 4.6, with 20% foetal
bovine serum.
2.3.ScanningElectron Microscopy. Theparasites weretreated
with concentrations of copaiba oil from C. reticulata that
inhibited 50% and 90% of growth (IC50 and IC90,r e s p . ) .
Promastigotes were treated with 5.0 and 80.0μg/mL at
25◦C, and axenic amastigote forms were treated with 15.0
and 70.0μg/mL at 32◦C. Next, the parasites were collected
by centrifugation after 72h incubation, washed in PBS
buﬀer, ﬁxed with 2.5% glutaraldehyde in 0.1M sodium
cacodylate buﬀer containing 1.0mM CaCl2. After ﬁxation,
smalldropsofthesamplewereplacedonaspecimensupport
with poly-L-lysine. The samples were then dehydrated in
graded ethanol, critical-point dried in CO2,c o a t e dw i t h
gold, and observed in a Shimadzu SS-550 scanning electron
microscope.
2.4. Transmission Electron Microscopy. Promastigote and
axenic amastigote forms of L. amazonensis were treated with
IC50 and IC90 of copaiba oil. After that, the samples were
processedfortransmissionelectronmicroscopy.Parasitecells
were harvested and washed twice with PBS buﬀer, and ﬁxed
with 2.5% glutaraldehyde in 0.1M sodium cacodylate buﬀer
at 4◦C, postﬁxed in a solution containing 1% OsO4,0 . 8 %
potassium ferrocyanide, and 10mM CaCl2 in 0.1M cacody-
late buﬀer, dehydrated in an increasing acetone gradient,
and embedded in Epon resin. Next, ultrathin sections were
stained with uranyl acetate and lead citrate, and images were
obtained in a Zeiss 900 TEM.
2.5. Measurement of Mitochondrial Membrane Potential. The
mitochondrial membrane potential was measured in L.
amazonensis axenic amastigotes using Rhodamine 123 (Rh
123) reagent, following the manufacturer’s protocol. Brieﬂy,
axenic amastigotes (5 × 106 parasites/mL) after treatment
with copaiba oil from C. reticulata (100, 150, 200μg/mL
for 3h at 32◦C) or untreated cells were harvested and
washed with PBS buﬀer. After that, the cells were incubated
with Rh 123 (5mg/mL for 30min at 37◦C) and washed
twice with PBS buﬀer. The mean ﬂuorescence intensity was
analysed using FACSCalibur and CellQuest software. A total
of 10,000 events were acquired in the region established as
that corresponding to the parasites. The compound carbonyl
cyanide m-chlorophenylhydrazone (CCCP) was used as a
positive control.
2.6. Measurement of Cell Viability. Cell viability was checked
by staining the cells with propidium iodide (PI). Axenic
amastigotes treated with copaiba oil from C. reticulata (100
and 200μg / m Lf o r3 ha t3 2 ◦C) or untreated amastigotes
were harvested and washed with PBS buﬀer. Then, the
parasite cells were stained with PI (20μg/mL for 5min)
as per instructions given by the manufacturer. The mean
ﬂuorescence intensity of the cells was analysed by ﬂow
cytometry, using FACSCalibur and CellQuest software. A
total of 10,000 events were acquired in the region established
as that corresponding to the parasites. Amphotericin B was
used as a positive control.
2.7. Statistical Analysis. The comparison between the values
of ﬂuorescence for Rh123 and PI was performed with the
program GraphPad Prism 4 (GraphPad Software, San Diego,
CA, USA). Student’s t-test was applied, and a P-value less
than.05wasregardedassigniﬁcant.Themeansandstandard
deviations were determined from at least three experiments.
3. Results and Discussion
Copaiba oils obtained from diﬀerent species of Copaifera
showed activity against promastigote forms of L. amazonen-
sis. Signiﬁcant antileishmanial activity of copaiba oil from
C. reticulata was demonstrated against axenic amastigote
and intracellular amastigote forms of the parasite with
IC50 values of 15.0μg/mL and 20.0μg/mL, respectively. As
reported recently, the major component of C. reticulata is β-
caryophyllene (40.9%) [25]. Therefore, the antileishmanial
activity of β-caryophyllene was tested against all forms
of the parasite. However, β-caryophyllene did not show
antileishmanial activity against amastigote-like forms, com-
pared with copaiba oil (data not shown). Some investigators
have attributed the biological activities of copaiba oil to the





Figure 1: Scanning electron micrographs of promastigote and axenic amastigote forms of L. amazonensis treated with copaiba oil for 72h.
(a) promastigote, control; (b) promastigote after treatment with IC50 of copaiba oil; (c and d) promastigote after treatment with IC90 of
copaiba oil; (e) amastigote, control; (f) amastigote after treatment with IC50 of copaiba oil; (g and h) amastigote after treatment with IC90 of
copaiba oil. Bars = 1μm.
which might aﬀect the active component by a synergistic
eﬀect [27]. Additionally, Lima et al. [28] reported that
fractionation of copaiba oils results in fractions that are less
active than the crude oil itself.
These results led us to investigate the morphological
and ultrastructural changes in L. amazonensis treated with
copaiba oil from C. reticulata, using electron microscopy.
As observed by scanning electron microscopy, promastigote
and axenic amastigote forms treated with copaiba oil showed
notablemorphologicalchanges(Figure 1).Untreatedcontrol
promastigotes showed the typical elongated shape with a
single ﬂagellum (Figure 1(a)), and axenic amastigotes a
rounded shape (Figure 1(e)). The typical morphology of
promastigotes and axenic amastigotes changed drastically
after treatment with copaiba oil. Promastigote forms treated
with copaiba oil showed a rounded shape with two ﬂag-
ella (Figure 1(b)). In amastigote-like forms, treatment with
copaiba oil led to rupture of the plasma membrane with
loss of their contents (Figures 1(f) and 1(g)). Additionally,
both forms showed protein denaturation of the cell surface
(Figures 1(c), 1(d), 1(g),a n d1(h)). Several studies have
found that the cell surface (carbohydrates associated with
lipids to form glycolipids) of parasitic protozoa plays an
important role in various processes including cell recog-
nition, cell adhesion, regulation of cell growth, expression






































Figure 2: Ultrastructural eﬀect of copaiba oil after incubation for 72h on promastigote and axenic amastigote forms of L. amazonensis,
observed by transmission electron microscopy. (a) promastigote control; (b) promastigote treated with IC50 of copaiba oil; (c and d)
promastigote treated with IC90 of copaiba oil; (e) amastigote, control; (f) amastigote treated with IC50 of copaiba oil; (g and h) amastigote
treated with IC90 of copaiba oil. Bars = 1μm. The treatment with copaiba oil led to changes in the mitochondria (m), exocytic activity in the
regionoftheﬂagellarpocket(asterisk),andcytoplasmicvacuolisation(whitestar).n,nucleus;f,ﬂagellum;fp,ﬂagellarpocket;k,kinetoplast;
m, mitochondrion.
surface changes caused by copaiba oil treatment may aﬀect
the parasite-host interaction, decreasing the infectivity of
the parasite. After treating the intracellular amastigotes with
copaiba oil from C. reticulata, Santos et al. [25]o b s e r v e da
dose-dependent decrease of parasites in the host peritoneal
macrophages. The cell viability of axenic amastigotes of L.
amazonensis was checked by staining the cells with propid-
ium iodide (PI), a ﬂuorescent dye that binds speciﬁcally to
DNA. In untreated axenic amastigotes, the degree of binding
of PI was 1.86%. Following treatment of axenic amastigotesEvidence-Based Complementary and Alternative Medicine 5


































































Figure 3: Flow cytometry analysis of L. amazonensis axenic amastigotes treated with copaiba oil and stained with propidium iodide (PI),
showing a decrease of cell viability in treated cells, (a) Untreated cells (b) amphotericin-B; (c) amastigotes treated with 100μg/mL; (d)
amastigotes treated with 200μg/mL. The numbers in bold show the percentage of PI-stained positive cells in the upper left quadrant.
with copaiba oil at 100μg/mL and 200μg/mL for 3h, the
gated percentage of PI-stained cells increased to 44.4% and
39.7%, respectively (Figure 3, upper-left quadrant). These
results were similar to the positive control amphotericin B
(32.78% treated with 5μg/mL; Figure 3, upper-left quad-
rant). All treatments were applied for 3h at 32◦C. Student’s
t-test (P<. 05) indicated signiﬁcant diﬀerences between
the group treated with copaiba oil compared to the negative
control group. These data may indicate that in axenic
amastigotes, copaiba oil induces a considerable increase in
plasma-membrane permeability. Ultrastructural changes in
promastigote and axenic amastigote forms of L. amazonensis
treated with the copaiba oil from C. reticulata are illustrated
in Figure 2. Control cells (Figures 2(a) and 2(e)) showed
no plasma membrane alterations, a nucleus with a normally
centred nucleolus, a kinetoplast, a mitochondrion with well-
deﬁned mitochondrial crypts, and a ﬂagellar pocket with
only one ﬂagellum, or the short ﬂagellum of the amastigote-
like form is within a distended ﬂagellar pocket. In both the
promastigoteandamastigote-likeforms,themostprominent
eﬀect of the treatment was swollen mitochondria (Figures
2(b), 2(c), 2(d),a n d2(f)). The copaiba oil treatment
also induced intense exocytic activity in the region of the
ﬂagellar pocket (Figure 2(g)) and cytoplasmic vacuolisation
(Figure 2(h)). Alterations in the mitochondrial membrane
potential of L. amazonensis amastigotes were studied by
treatment with copaiba oil for 3h at 32◦C and stained with
Rh-123 as described in Methods. Mitochondrial energizing
induces quenching of Rh-123 ﬂuorescence, and the rate
of ﬂuorescence decay is proportional to the mitochondrial
membrane potential. Data obtained from ﬂow cytometry by
using Rh123 showed a marked decrease in the percentage
population of the upper right gated (49.11% and 38.76%),
indicating depolarization of the mitochondrial membrane
potential in the cells following treatment with copaiba oil
at 100μg/mL and 200μg/mL, respectively (Figure 4). Simi-
larly, a decrease in membrane potentials was also observed
followingtreatmentwiththestandard drugcarbonylcyanide
m-chlorophenylhydrazone (CCCP) (76.4%) at 200μMf o r
3h at 32 ◦C. In contrast, untreated cells maintained the6 Evidence-Based Complementary and Alternative Medicine






















































































Figure 4: Flow cytometry analysis of Rh123-labeled axenic amastigotes of L. amazonensis. Copaiba oil collapsed the ΔΨm, leading to parasite
death. (a) untreated cells; (b) CCCP 200μM; (c) amastigotes treated with 100μg/mL; (d) amastigotes treated with 200μg/mL. The numbers
in bold represent the percentage of collapsed ΔΨm cells in the upper right quadrant.
membrane potential (98.78%) (Figure 4;u p p e rr i g h tq u a d -
rant). Student’s t-test (P<. 05) indicated signiﬁcant
diﬀerences between cells treated copaiba oil compared to the
negative control group. The maintenance of mitochondrion
properties, including the mitochondrial membrane potential
(ΔΨm), synthesis of ATP, and oxidative phosphorylation,
is essential for the survival of Leishmania, because these
parasites have a single mitochondrion [32–34]. Accordingly,
the loss of the mitochondrial membrane potential is one
indicationofdamageobservedintheultrastructuralanalyses
and might lead to the death of the parasites.
In conclusion, the copaiba oil caused notable morpho-
logical and ultrastructural changes in the treated parasites
compared with the untreated cells. In both forms of L. ama-
zonensis, copaiba oil caused extensive mitochondrial damage
and also led to plasma membrane denaturation. Since
morphological and ultrastructural analysis demonstrated
that treatment with copaiba oil induced alterations in the
membraneandmitochondrionoftheparasites,weincubated
treated parasites with PI and Rh123. L. amazonensis treated
with copaiba oil showed a decrease in Rh123 ﬂuorescence,
suggesting an eﬀect on the mitochondrial membrane poten-
tial. Staining of the parasite cells with PI demonstrated
that loss of cell viability occurred due to an increase in
permeability of the plasma membrane. Therefore, it appears
that copaiba oil could be exploited for the development of
new antileishmanial drugs.
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